R. C. Ribeiro, F. Sandrini, B. Figueiredo, G. P. Zambetti, E. Michalkiewicz et al., An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma, Proc. Natl. Acad. Sci, vol.98, pp.9330-9335, 2001.

A. C. Latronico, E. M. Pinto, S. Domenice, M. C. Fragoso, R. M. Martin et al., An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors, J. Clin. Endocrinol. Metab, vol.86, pp.4970-4973, 2001.

M. A. Pianovski, E. M. Maluf, D. S. De-carvalho, R. C. Ribeiro, C. Rodriguez-galindo et al., Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatr. Blood Cancer, vol.47, pp.56-60, 2006.

G. Custodio, G. A. Parise, N. Filho, H. Komechen, C. C. Sabbaga et al., Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors, J. Clin. Oncol, vol.31, pp.2619-2626, 2013.

E. Michalkiewicz, R. Sandrini, B. Figueiredo, E. C. Miranda, E. Caran et al., Clinical and outcome characteristics of children with adrenocortical tumors: A report from the International Pediatric Adrenocortical Tumor Registry, J. Clin. Oncol, vol.22, pp.838-845, 2004.

A. P. Dackiw, J. E. Lee, R. F. Gagel, and D. B. Evans, Adrenal cortical carcinoma. World J. Surg, vol.25, pp.914-926, 2001.

B. C. Figueiredo, R. C. Ribeiro, G. Zambetti, B. Haddad, M. D. Pianovsky et al., Amplification of 9q34 in childhood adrenocortical tumors: A specific feature unrelated to ethnic origin or living conditions. Braz, J. Med. Biol. Res, vol.33, pp.1217-1224, 2000.

G. Custodio, H. Komechen, F. R. Figueiredo, N. D. Fachin, M. A. Pianovski et al., Molecular epidemiology of adrenocortical tumors in southern Brazil, Mol. Cell. Endocrinol, vol.351, pp.44-51, 2012.

E. Lalli and B. C. Figueiredo, Pediatric adrenocortical tumors: What they can tell us on adrenal development and comparison with adult adrenal tumors, Front. Endocrinol

C. Rodriguez-galindo, B. C. Figueiredo, G. P. Zambetti, and R. C. Ribeiro, Biology, clinical characteristics, and management of adrenocortical tumors in children, Pediatr. Blood Cancer, vol.45, pp.265-273, 2005.

A. Berruti, M. Terzolo, A. Pia, A. Angeli, and L. Dogliotti, Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer, Cancer, vol.83, pp.2194-2200, 1998.

P. Zancanella, M. A. Pianovski, B. H. Oliveira, S. Ferman, G. C. Piovezan et al., Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: Mitotane monitoring and tumor regression, J. Pediatr. Hematol. Oncol, vol.28, pp.513-524, 2006.

C. Rodriguez-galindo, A. S. Pappo, M. D. Krailo, F. Pashankar, E. M. Caran et al., Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children's Oncology Group ARAR0332 protocol, J. Clin. Oncol, vol.34, 2016.

E. M. Pinto, X. Chen, J. Easton, D. Finkelstein, Z. Liu et al., Genomic landscape of paediatric adrenocortical tumours, Nat. Commun, vol.6, 2015.

C. L. Ronchi, S. Sbiera, E. Leich, K. Henzel, A. Rosenwald et al., Single nucleotide polymorphism array profiling of adrenocortical tumors-evidence for an adenoma carcinoma sequence?, PLoS ONE, vol.8, 2013.

L. P. Dehner, Pediatric adrenocortical neoplasms: On the road to some clarity, Am. J. Surg. Pathol, vol.27, pp.1005-1007, 2003.

J. A. Wieneke, L. D. Thompson, and C. S. Heffess, Adrenal cortical neoplasms in the pediatric population: A clinicopathologic and immunophenotypic analysis of 83 patients, Am. J. Surg. Pathol, vol.27, pp.867-881, 2003.

J. P. Mcateer, J. A. Huaco, and K. W. Gow, Predictors of survival in pediatric adrenocortical carcinoma: A Surveillance, Epidemiology, and End Results (SEER) program study, J. Pediatr. Surg, vol.48, pp.1025-1031, 2013.

R. Morimoto, F. Satoh, O. Murakami, T. Suzuki, T. Abe et al., Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas, Endocr. J, vol.55, pp.49-55, 2008.

E. Duregon, L. Molinaro, M. Volante, L. Ventura, L. Righi et al., Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma, Mod. Pathol, vol.27, pp.1246-1254, 2014.

F. Beuschlein, J. Weigel, W. Saeger, M. Kroiss, V. Wild et al., Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection, J. Clin. Endocrinol. Metab, vol.100, pp.841-849, 2015.

E. M. Pinto, C. Rodriguez-galindo, S. B. Pounds, L. Wang, M. R. Clay et al., Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study, J. Clin. Oncol, vol.35, pp.3956-3963, 2017.

R. Libe, I. Borget, C. L. Ronchi, B. Zaggia, M. Kroiss et al., Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): An European Network for the Study of Adrenal Tumor (ENSAT) study, Ann. Oncol, vol.26, pp.2119-2125, 2015.

S. K. Lau and L. M. Weiss, The Weiss system for evaluating adrenocortical neoplasms: 25 years later, Hum. Pathol, vol.40, pp.757-768, 2009.

M. Pennanen, I. Heiskanen, T. Sane, S. Remes, H. Mustonen et al., Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas, Hum. Pathol, vol.46, pp.404-410, 2015.

E. Duregon, R. Cappellesso, V. Maffeis, B. Zaggia, L. Ventura et al., Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma, Hum. Pathol, vol.62, pp.1-7, 2017.

I. Bergada, M. Venara, S. Maglio, M. Ciaccio, B. Diez et al., Functional adrenal cortical tumors in pediatric patients: A clinicopathologic and immunohistochemical study of a long term follow-up series, Cancer, vol.77, pp.771-777, 1996.

A. E. Coutinho and K. E. Chapman, The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights, Mol. Cell. Endocrinol, vol.335, pp.2-13, 2011.

D. W. Cain and J. A. Cidlowski, Immune regulation by glucocorticoids, Nat. Rev. Immunol, vol.17, pp.233-247, 2017.

M. E. Chamuleau, G. J. Ossenkoppele, and A. A. Van-de-loosdrecht, MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation, Immunobiology, vol.211, pp.619-625, 2006.

M. Campoli and S. Ferrone, HLA antigen and NK cell activating ligand expression in malignant cells: A story of loss or acquisition, Semin. Immunopathol, vol.33, pp.321-334, 2011.

K. Chamoto, M. Al-habsi, and T. Honjo, Role of PD-1 in Immunity and Diseases, Curr. Top. Microbiol. Immunol, vol.410, pp.75-97, 2017.

D. J. Leahy, R. Axel, and W. A. Hendrickson, Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 A resolution, Cell, vol.68, pp.1145-1162, 1992.

T. Okazaki and T. Honjo, PD-1 and PD-1 ligands: From discovery to clinical application, Int. Immunol, vol.19, pp.813-824, 2007.

S. L. Topalian, C. G. Drake, and D. M. Pardoll, Immune checkpoint blockade: A common denominator approach to cancer therapy, Cancer Cell, vol.27, pp.450-461, 2015.

M. A. Postow, M. K. Callahan, and J. D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy, J. Clin. Oncol, vol.33, 1974.

M. Swart, I. Verbrugge, and J. B. Beltman, Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy, Front. Oncol, vol.6, p.233, 2016.

Y. Ohigashi, M. Sho, Y. Yamada, Y. Tsurui, K. Hamada et al., Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer, Clin. Cancer Res, vol.11, pp.2947-2953, 2005.

E. N. Rozali, S. V. Hato, B. W. Robinson, R. A. Lake, and W. J. Lesterhuis, Programmed death ligand 2 in cancer-induced immune suppression, Clin. Dev. Immunol, 2012.

A. P. Fay, S. Signoretti, M. Callea, G. H. Telomicron, R. R. Mckay et al., Programmed death ligand-1 expression in adrenocortical carcinoma: An exploratory biomarker study, J. Immunother. Cancer, vol.3, 2015.

J. F. Tierney, A. Vogle, J. Poirier, I. M. Min, B. Finnerty et al., Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study, Surgery, vol.165, pp.196-201, 2019.

L. Tourneau, C. Hoimes, C. Zarwan, C. Wong, D. J. Bauer et al., Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial, J. Immunother. Cancer, vol.6, 2018.

B. J. Van-den-eynde and T. Boon, Tumor antigens recognized by T lymphocytes, Int. J. Clin. Lab. Res, vol.27, pp.81-86, 1997.

A. F. Kirkin, K. Dzhandzhugazyan, and J. Zeuthen, Melanoma-associated antigens recognized by cytotoxic T lymphocytes, APMIS, vol.106, pp.665-679, 1998.

G. Zeng, MHC class II-restricted tumor antigens recognized by CD4+ T cells: New strategies for cancer vaccine design, J. Immunother, vol.24, pp.195-204, 2001.

Y. Naito, K. Saito, K. Shiiba, A. Ohuchi, K. Saigenji et al., CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer, Cancer Res, vol.58, pp.3491-3494, 1998.

S. Vesalainen, P. Lipponen, M. Talja, and K. Syrjanen, Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma, Eur. J. Cancer, vol.30, pp.1797-1803, 1994.

L. P. Setala, V. M. Kosma, S. Marin, P. K. Lipponen, M. J. Eskelinen et al., Prognostic factors in gastric cancer: The value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration, Br. J. Cancer, vol.74, pp.766-772, 1996.

S. Ishigami, S. Natsugoe, K. Tokuda, A. Nakajo, H. Higashi et al., CD3-zetachain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients, Cancer, vol.94, pp.1437-1442, 2002.

P. Pisarra, R. Mortarini, S. Salvi, A. Anichini, G. Parmiani et al., High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition, Cancer Immunol. Immunother, vol.48, pp.39-46, 1999.

A. Ladanyi, B. Somlai, K. Gilde, Z. Fejos, I. Gaudi et al., T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma, Clin. Cancer Res, vol.10, pp.521-530, 2004.

H. Echchakir, I. Vergnon, G. Dorothee, D. Grunenwald, S. Chouaib et al., Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung, Int. Immunol, vol.12, pp.537-546, 2000.

L. Zhang, J. R. Conejo-garcia, D. Katsaros, P. A. Gimotty, M. Massobrio et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N. Engl. J. Med, vol.348, pp.203-213, 2003.

S. Kondratiev, E. Sabo, E. Yakirevich, O. Lavie, and M. B. Resnick, Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma, Clin. Cancer Res, vol.10, pp.4450-4456, 2004.

K. Wang, T. Shen, G. P. Siegal, and S. Wei, The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer, Hum. Pathol, vol.69, pp.110-117, 2017.

A. Jouinot and J. Bertherat, Management of Endocrine Disease: Adrenocortical carcinoma: Differentiating the good from the poor prognosis tumors, Eur. J. Endocrinol, vol.178, pp.1730-1746, 2018.

S. Zheng, A. D. Cherniack, N. Dewal, R. A. Moffitt, L. Danilova et al., Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, vol.29, pp.723-736, 2016.

N. P. Weng, Y. Araki, and K. Subedi, The molecular basis of the memory T cell response: Differential gene expression and its epigenetic regulation, Nat. Rev. Immunol, vol.12, pp.306-315, 2012.

I. Zlobec, V. H. Koelzer, H. Dawson, A. Perren, and A. Lugli, Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: An example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types, J. Transl. Med, issue.11, 2013.

A. Marchetti, M. Barberis, R. Franco, G. De-luca, M. V. Pace et al., Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors, J. Thorac. Oncol, vol.12, pp.1654-1663, 2017.

A. D'incecco, M. Andreozzi, V. Ludovini, E. Rossi, A. Capodanno et al., PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br. J. Cancer, vol.112, pp.95-102, 2015.

. R-core-team, R: Language and Environment for Statistical Computing; R Foundation for Statistical Computing, 2014.

L. M. Weiss, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors, Am. J. Surg. Pathol, vol.8, pp.163-169, 1984.

C. Fiorentini, S. Grisanti, D. Cosentini, A. Abate, E. Rossini et al., Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma, J. Oncol, 2019.

T. Boon, J. C. Cerottini, B. Van-den-eynde, P. Van-der-bruggen, and A. Van-pel, Tumor antigens recognized by T lymphocytes, Annu. Rev. Immunol, vol.12, pp.337-365, 1994.

L. J. Old and Y. Chen, New paths in human cancer serology, J. Exp. Med, vol.187, pp.1163-1167, 1998.